NCT04762199View on ClinicalTrials.gov

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

December 27, 2025

Study Completion Date

December 27, 2026

Conditions
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
DRUG

Flt3/MerTK Inhibitor MRX-2843

Given PO

DRUG

Osimertinib

Given PO

Trial Locations (1)

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER